Nath Bio-Genes (India) Ltd. (NATHBIOGEN) AI Stock Analysis

• Market Cap: ₹2.90B
• Dividend Yield: 1.26%
• Average Volume (3M): 2.58K
• Price to Earnings (P/E): 46.0
• Beta (1Y): 1.20
• Revenue Growth: 18.68%
• EPS Growth: 16.47%
• Country: IN
• Employees: 423
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Agricultural Inputs
• EPS (TTM): 0.84
• Shares Outstanding: 19,004,000
• 10 Day Avg. Volume: 2,256
• 30 Day Avg. Volume: 2,581
• PEG Ratio: -3.00
• Price to Book (P/B): 0.47
• Price to Sales (P/S): 0.82
• P/FCF Ratio: 31.02
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 66 Neutral
• Price Target: ₹186.00 ▲(17.13% Upside)
• Action: Reiterated Date: 04/14/26
• Date: Action: Reiterated 04/14/26

The score is driven primarily by solid financial performance (profitability and growth with reasonable balance-sheet strength) and strong technical uptrend signals. These positives are meaningfully offset by expensive valuation (high P/E with modest yield) and overbought momentum indicators that elevate near-term risk.

Positive Factors

Revenue Growth

Sustained revenue growth (25% YoY) indicates expanding adoption of the company’s hybrid and improved seed portfolio across field crops. Durable top-line momentum supports reinvestment in R&D, scaling distribution, and helps smooth returns across seasonal cycles.

Negative Factors

Cash Flow Variability

Variable free cash flow conversion creates liquidity uncertainty across planting seasons. This can constrain timely investment in seed R&D, processing upgrades and working capital for peak sowing periods, making operations sensitive to collection and inventory timing.

Nath Bio-Genes (India) Ltd. Business Overview & Revenue Model

Company Description

Nath Bio-Genes (India) Limited engages in the production, processing, and marketing of hybrid and GM seeds in India and internationally. It operates in two segments, Agricultural Activities and Trading Activities. The company offers seeds for cere...

Read more

Nath Bio-Genes (India) Limited engages in the production, processing, and marketing of hybrid and GM seeds in India and internationally. It operates in two segments, Agricultural Activities and Trading Activities. The company offers seeds for cere...

How the Company Makes Money

The company primarily makes money by selling crop seeds to the agricultural market. Its core revenue stream is the sale of proprietary and licensed seed products (commonly including hybrid and improved varieties), distributed through agricultural ...

Read more

The company primarily makes money by selling crop seeds to the agricultural market. Its core revenue stream is the sale of proprietary and licensed seed products (commonly including hybrid and improved varieties), distributed through agricultural ...

Nath Bio-Genes (India) Ltd. Financial Statement Overview

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	4.16B	3.65B	2.48B	3.01B	2.78B	3.07B
Gross Profit	2.18B	2.29B	1.03B	1.67B	1.54B	1.71B
EBITDA	629.40M	497.98M	536.39M	488.91M	-497.06M	684.33M
Net Income	462.29M	386.00M	396.19M	350.11M	-673.38M	556.62M
Balance Sheet
Total Assets	10.14B	10.26B	8.80B	7.93B	7.42B	7.90B
Cash, Cash Equivalents and Short-Term Investments	1.59B	888.99M	774.10M	379.90M	41.68M	292.11M
Total Debt	1.55B	1.23B	1.10B	1.05B	929.59M	965.67M
Total Liabilities	3.34B	3.82B	2.70B	2.20B	2.00B	1.76B
Stockholders Equity	6.80B	6.44B	6.10B	5.73B	5.42B	6.13B
Cash Flow
Free Cash Flow	-1.10B	96.61M	478.18M	358.18M	-39.70M	-104.86M
Operating Cash Flow	-1.09B	175.81M	745.94M	383.67M	170.46M	11.13M
Investing Cash Flow	-11.48M	-39.62M	-274.01M	-28.84M	-198.66M	-102.82M
Financing Cash Flow	216.74M	-21.30M	-77.78M	-16.68M	-222.27M	164.01M

Nath Bio-Genes (India) Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 158.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NATHBIOGEN, the sentiment is Positive. The current price of 158.8 is above the 20-day moving average (MA) of 142.22, above the 50-day MA of 145.51, and below the 200-day MA of 164.77, indicating a bullish trend. The MACD of 2.86 indicates Negative momentum. The RSI at 76.25 is Negative, neither overbought nor oversold. The STOCH value of 85.97 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:NATHBIOGEN.

Nath Bio-Genes (India) Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HARRMALAYA	70 Outperform	₹3.51B	10.14	―	―	4.81%	―
NATHBIOGEN	66 Neutral	₹2.90B	46.03	―	1.26%	18.68%	16.47%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
ARIES	62 Neutral	₹4.94B	6.17	―	0.38%	13.83%	33.88%
NOVAAGRI	59 Neutral	₹2.69B	33.21	―	―	13.15%	-20.51%

Nath Bio-Genes (India) Ltd. Corporate Events